Hedge Fund ValueAct Bullish On Valeant Pharmaceuticals Intl Inc (VRX) – Letter

HFA Padded
Rupert Hargreaves
Published on
Updated on

Valeant Pharmaceuticals Intl Inc has many well-known and vocal supporters in the hedge fund industry. Bill Ackman is perhaps the most notable of these advocates, due to the hedge fund billionaire’s oversized position in the former market darling. Jeffrey Ubben’s ValueAct Capital also owns a significant stake in the drug maker. According to the fund’s most recent 13F filing, ValueAct owned just under 15 million shares of Valeant at the end of the fourth quarter, around 10.6% of the hedge fund’s equity portfolio at the time making it the fund’s second-largest holding after Microsoft (21.8% of the fund’s equity portfolio)….

This content is exclusively for paying members of Hedge Fund Alpha

Log In

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe now and get 7 days free!

HFA Padded

Sign up now and get our in-depth FREE e-books on famous investors like Klarman, Dalio, Schloss, Munger Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors. Rupert owns shares in Berkshire Hathaway. Rupert holds qualifications from the Chartered Institute For Securities & Investment and the CFA Society of the UK. Rupert covers everything value investing for ValueWalk

Comments are closed.